Situation and suggestion on the pharmacotherapy before and after the percutaneous coronary intervention in Beijing hospital

Abstract

Abstract: AIM: To evaluate the status quo and rationality of medicinal application for patients undergoing percutaneous coronary intervention (PCI) through therapeutic guide of 2009 and 2012.METHODS: Patients who underwent coronary heart disease (CHD) from the department of cardiology of Beijing hospital were included. The medicinal use before and after PCI were analyzed.RESULTS: All the enrolled 73 CHD patients had indications, with 44 patients for coronary angiography and 29 patients for PCI. The percentage of antiplatelet therapy was 100%. 27% patients were using anticoagulant drugs. 74% patients were taking β-blocker and 73% for ACEI or ARB, 96% for plasma lipids regulators.CONCLUSION: There are a gap between evidence and practice. It remains a major challenge for doctors, pharmacists, healthcare professionals and policy makers to resolve this problem rapidly.

Key words: PCI, Medicine evaluation, Secondary prevention

CLC Number:

GAO Ru-ya ZHANG Ya-tong, CAO Guo-ying. Situation and suggestion on the pharmacotherapy before and after the percutaneous coronary intervention in Beijing hospital[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(10): 1110-1115.

References

[1] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 经皮冠状动脉介入治疗指南(2009)[J]. 中华心血管杂志, 2009, 1(37): 4-25.
[2] 中华医学会心血管病学分会介入心脏病学组, 中华心血管病杂志编辑委员会. 中国经皮冠状动脉介入治疗指南2012(简本)[J]. 中华危重症医学杂志, 2012, 3 (9): 18-26
[3] 张艳, 陈慧, 孙红, 等. 肠溶阿司匹林在冠心病治疗中致上消化道出血的相关因素分析[J]. 医学综述, 2010, 6(16): 1918-1920.
[4] 陈慧, 张艳, 吴小盈, 等. 肠溶阿司匹林致冠心病患者上消化道出血不良反应调查[J]. 中华临床医师杂志(电子版), 2010, 8(4): 1277-1281.
[5] 夏志荣, 俞坚武. 波利维和泰嘉在冠心病治疗中的疗效和经济学对比分析[J]. 中国全科医学,2011, 14(6): 661-663.
[6] 贺春晖, 胡琴, 邹建军, 等. 氯吡格雷抵抗的基因多态性探讨[J]. 中国临床药理学与治疗学, 2010, 15(11): 1288-1293.
[7] 杨莉萍, 谢婧, 刘瑶, 等. CYP2C19^*2、^*3基因多态性与氯吡格雷临床疗效相关性的系统评价[J].中国循证医学杂志, 2012, 12(9): 1063-1070.
[8] Gurm HS, Bhatt DL, Lincoff AM, et al. Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials [J]. Heart, 2003, 89(10): 1200-1204.
[9] 陈平, 马依彤. 血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂在急性冠脉综合征中的应用进展[J]. 心血管病学进展, 2010, 31(6): 843-846.
[10] 王雪梅, 李鹏. 盐酸替罗非班在冠心病治疗中的进展[J]. 医学综述, 2009, 15(18): 2791-2793.
[11] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. β肾上腺素能受体阻滞剂在心血管疾病应用专家共识[J]. 中华心血管病杂志, 2009, 3(37):195-209.
[12] 吕树铮, 王立新. 糖尿病合并冠心病流行病学现状与研究进展[J]. 中华老年心脑血管病杂志, 2009, 12(11): 910-911.